# Article information:

Comprehensive Characterisation of the Innovator Product: Targeting Bioequivalent Generics - Vishal S. Koradia, Garima Chawla, Arvind K. Bansal, 2005
<https://journals.sagepub.com/doi/abs/10.1057/palgrave.jgm.4940086>

# Article summary:

1. The article discusses the development of a generic product, which requires therapeutic equivalence to the innovator product in order to ensure comparable efficacy and safety.

2. A methodology for characterisation of ranitidine hydrochloride tablets was developed, with special emphasis on the solid-state characterisation of the active pharmaceutical ingredient (API).

3. Differential solubility methods, microscopic techniques, thermal techniques, spectroscopic techniques and crystallographic techniques were used to characterise the solid-state properties of the API in the tablet.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article is generally reliable and trustworthy as it provides a comprehensive overview of the development process for generic products and how they can be made therapeutically equivalent to their innovator counterparts. The authors provide detailed information on the various techniques used for characterising ranitidine hydrochloride tablets, such as differential solubility methods, microscopic techniques, thermal techniques, spectroscopic techniques and crystallographic techniques. The authors also provide references to relevant literature that supports their claims.

However, there are some potential biases in the article that should be noted. For example, there is no mention of any potential risks associated with developing generic products or any counterarguments that could be raised against them. Additionally, there is no discussion of any possible alternatives to developing generic products or any other potential solutions that could be explored. Furthermore, there is no mention of any promotional content or partiality in favour of generic products over innovator products.

In conclusion, while this article provides a comprehensive overview of the development process for generic products and how they can be made therapeutically equivalent to their innovator counterparts, it does not explore all possible risks associated with developing such products nor does it present both sides equally without bias or promotional content.

# Topics for further research:

* Risks associated with generic products
* Alternatives to generic products
* Innovator products vs generic products
* Regulatory requirements for generic products
* Promotional content for generic products
* Therapeutic equivalence of generic products

# Report location:

<https://www.fullpicture.app/item/42ab19363c7134728889c498a9e569da>